Viral Infections
RSSArticles
-
2022-2023: A Severe Season for Respiratory Syncytial Virus
The 2022-2023 northern hemisphere respiratory syncytial virus (RSV) season began with fury, crowding hospitals and making many young children extremely ill. Meanwhile, advancing research points to potential means of better preventing RSV infection.
-
Resistance of SARS-CoV-2 Variants to Monoclonal Antibodies
Prevalent SARS-CoV-2 variants are increasingly resistant to therapeutic and prophylactic monoclonal antibodies but remain susceptible to Paxlovid, remdesivir, and molnupiravir.
-
Vaccination Against Mpox: Does it Work? Is it Safe?
Vaccination, either subcutaneously or intradermally, with the non-replicating JYNNEOS vaccine is safe and effective.
-
Congress Issues Special Report on COVID-19 Pandemic
A select subcommittee exhaustively detailed what went wrong and offered suggestions on how to prevent future disasters.
-
Global Health Officials Announce Updated Name for Monkeypox
The traditional name will be phased out in favor of “mpox.”
-
2022-2023: A Severe Season for Respiratory Syncytial Virus
The 2022-2023 northern hemisphere respiratory syncytial virus (RSV) season began with fury, crowding hospitals and making many young children extremely ill. Meanwhile, advancing research points to potential means of better preventing RSV infection.
-
Severe Monkeypox
The Centers for Disease Control and Prevention has summarized 57 cases of individuals hospitalized with severe monkeypox, most of whom were immunocompromised men and a number of whom had delayed initiation of antiviral therapy.
-
Genital Herpes — No Longer Just HSV-2 as HSV-1 Makes its Move
Viral shedding after a first episode of genital herpes simplex virus type 1, which is gradually replacing herpes simplex virus type 2 as the major cause of genital infection, occurred in 12.1% at weeks 8-12 and decreased to 7.1% at the end of one year.
-
Infectious Disease Alert Updates
Animal Reservoirs for Human Infection; Novel Rat-Derived HEV Infection in Humans; Household Contamination with Monkeypox
-
Evidence of Clinical Efficacy of Bebtelovimab in COVID-19
In a retrospective study, bebtelovimab demonstrated efficacy similar to Paxlovid in high-risk outpatients with recent onset of COVID-19 who reported mild to moderate symptoms.